| Matthew Tyler Hunter, DO | |
|
P36 1st St. W, Fort Drum, NY 13650 | |
| (315) 772-2557 | |
| Not Available |
| Full Name | Matthew Tyler Hunter |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | P36 1st St. W, Fort Drum, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831696426 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 0102205904 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Matthew Tyler Hunter, DO 11050 Mount Belvedere Blvd, Fort Drum, NY 13602 Ph: () - | Matthew Tyler Hunter, DO P36 1st St. W, Fort Drum, NY 13650 Ph: (315) 772-2557 |
News Archive
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.
Continuing a global effort to prevent malaria infections, Michigan State University researchers have created a new malaria vaccine - one that combines the use of a disabled cold virus with an immune system-stimulating gene - that appears to increase the immune response against the parasite that causes the deadly disease.
The US Food and Drug Administration announced today that the drug ipilimumab has been approved for the treatment of patients with metastatic melanoma. It is the first drug ever shown to improve overall survival for patients with advanced melanoma.
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system - called "complement" - that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.
Researchers from the Georgia Institute of Technology and the Centers for Disease Control and Prevention (CDC) have developed a new laboratory test that can rapidly identify the bacterium responsible for staph infections. This new test takes advantage of unique isotopic labeling combined with specific bacteriophage amplification to rapidly identify Staphylococcus aureus.
› Verified 3 days ago
John Lee Hirt, DO Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 11050 Mount Belvedere Blvd, Fort Drum, NY 13602 Phone: 315-774-5327 | |
Dr. Peter Saulius Armanas, D.O. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 11050 Mount Belvedere Boulevard, Fort Drum, NY 13602 Phone: 315-774-0118 | |
Kelly Macdonald, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: Usa Meddac, 11050 Mount Belvedere Blvd, Fort Drum, NY 13602 Phone: 315-772-2778 | |
Dr. Peter Leo Cuff, D.O. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 11050 Mount Belvedere Blvd, Fort Drum, NY 13602 Phone: 315-772-3924 | |
Andrew Slye, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 10000 10th Mountain Div Dr, Fort Drum, NY 13602 Phone: 315-774-0105 |